Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Ce mémoire a pour objectif d'analyser les différentes études cliniques qui ont été réalisées sur une nouvelle formulation orale de la lévodopa : IPX066, et déterminer, au terme d'une discussion, son intérêt et ses perspectives dans l'arsenal thérapeutique de la maladie de Parkinson. Actuellement, la lévodopa demeure le traitement le plus efficace pour contrôler les symptômes moteurs de la maladie de Parkinson. Pratiquement tous les patients en reçoivent au cours de leur maladie. Cependant, cela entraine presque inexorablement des complications motrices (fluctuations motrices et dyskinésies). Dans le but de les limiter, IPX066 a été développé et approuvé par l'EMA (Numient®) et la FDA (Rytary®) en 2015. Cette formulation contient des microbilles de carbidopa-lévodopa à libération immédiate et prolongée permettant une atteinte rapide et un maintien des concentrations plasmatiques thérapeutiques de lévodopa de façon plus continue. Cela entrainerait une stimulation dopaminergique plus constante et donc, une diminution des complications motrices liées à la lévodopa. The purpose of this thesis is to analyze several clinical studies conducted about a new levodopa oral formulation: IPX066 and to identify, following a discussion, its interest and prospects in Parkinson's disease therapeutic arsenal. Levodopa remains currently the most effective treatment managing the motor symptoms of Parkinson’s disease. Almost all patients receive it at some point. However, it leads almost inexorably to motor complications (motor fluctuations and dyskinesia’s). To limit it, IPX066 has been developed and approved by the EMA (Numient®) and FDA (Rytary®) in 2015. This formulation contains immediate and extended release microbeads of carbidopa-levodopa allowing a rapid onset and sustained and more continuous levodopa therapeutic plasma concentrations. lt would lead to more consistent dopaminergic stimulation and thus, a decrease in levodopa-induced motor complications.

Parkinson Disease --- Levodopa

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Levodopa --- Parkinson Disease --- therapeutic use. --- drug therapy.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Delayed-action preparations. --- Levodopa. --- Parkinson disease, drug therapy.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

HUMAN --- RORSCHACH TEST --- PARKINSON DISEASE --- LEVODOPA --- DRUG THERAPY --- THERAPEUTIC USE --- HUMAN --- RORSCHACH TEST --- PARKINSON DISEASE --- LEVODOPA --- DRUG THERAPY --- PSYCHOLOGY --- THERAPEUTIC USE

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact

neurodegenerative diseases --- movement disorders --- motor neuron disease --- non-motor symptoms ---  C9orf72 hexanucleotide repeat expansion --- neuropsychiatric disorders --- sleep disorders --- levodopa response